<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC7292951/results/search/drugs/results.xml">
  <result pre="The most common treatment of influenza is the use of" exact="acetaminophen" post="to relieve fever and muscle pain associated with the"/>
  <result pre="reported [6]. The analytes included anti-influenza drugs (amantadine, rimantadine, oseltamivir," exact="oseltamivir" post="carboxylate, memantine, arbidol, and moroxydine), anti-herpes drugs (acyclovir, ganciclovir,"/>
  <result pre="memantine, arbidol, and moroxydine), anti-herpes drugs (acyclovir, ganciclovir, famciclovir, penciclovir," exact="ribavirin" post="and its main metabolite TCONH2), and an immunomodulator (imiquimod)."/>
  <result pre="of the antiviral agents against Herpes viruses is reviewed. As" exact="ribavirin" post="is also used in HCV treatment, it was already"/>
  <result pre="152.0577 [C5H6N5]+ [[6], [7], [8],[12], [13], [14]] 135.030 [C5H3N4O]+ [6,8,13]" exact="cidofovir" post="280.069 [C8H14N3O6P]+ 282.059 [C8H13N3O5P]+ [15] famciclovir 322.151 [C14H20N5O4]+ 280.140"/>
  <result pre="[14]] 135.030 [C5H3N4O]+ [6,8,13] cidofovir 280.069 [C8H14N3O6P]+ 282.059 [C8H13N3O5P]+ [15]" exact="famciclovir" post="322.151 [C14H20N5O4]+ 280.140 [C12H18N5O3]+ [6] 136.062 [C5H6N5]+ [6] ganciclovir"/>
  <result pre="[15] famciclovir 322.151 [C14H20N5O4]+ 280.140 [C12H18N5O3]+ [6] 136.062 [C5H6N5]+ [6]" exact="ganciclovir" post="256.104 [C9H14N5O4]+ 152.0577 [C5H6N5]+ [6,[12], [13], [14],16] 135.030 [C5H3N4O]+"/>
  <result pre="256.104 [C9H14N5O4]+ 152.0577 [C5H6N5]+ [6,[12], [13], [14],16] 135.030 [C5H3N4O]+ [6,13,17]" exact="idoxuridine" post="354.979 [C9H12IN2O5]+ 117.055 [C5H9O3]+ [18] letermovir 573.212 [C29H29F4N4O4]+ 383.101"/>
  <result pre="[C9H12IN2O5]+ 117.055 [C5H9O3]+ [18] letermovir 573.212 [C29H29F4N4O4]+ 383.101 [C18H15F4N2O3]+ [18]" exact="penciclovir" post="254.125 [C10H16N5O3]+ 152.0577 [C5H6N5]+ [6,20,21] 135.030 [C5H3N4O]+ [6] pritelivir"/>
  <result pre="[6,20,21] 135.030 [C5H3N4O]+ [6] pritelivir 403.089 [C18H19N4O3S2]+ 196.076 [C13H10NO]+ [22,23]" exact="ribavirin" post="245.088 [C8H12N4O5]+ 113.046 [C3H5N4O]+ [6,8,24,25] 96.019 [C3H2N3O]+ [6,8] ribavirin"/>
  <result pre="[22,23] ribavirin 245.088 [C8H12N4O5]+ 113.046 [C3H5N4O]+ [6,8,24,25] 96.019 [C3H2N3O]+ [6,8]" exact="ribavirin" post="– Met: TCONH2, triazole carboxamide 113.046 [C3H5N4O]+ 96.019 [C3H2N3O]+"/>
  <result pre="triazole carboxamide 113.046 [C3H5N4O]+ 96.019 [C3H2N3O]+ [6] 69.008 [C2HN2O]+ [6]" exact="trifluridine" post="297.069 [C10H12F3N2O5]+ 117.055 [C5H9O3]+ [18] valaciclovir 325.162 [C13H21N6O4]+ 152.0577"/>
  <result pre="[6] 69.008 [C2HN2O]+ [6] trifluridine 297.069 [C10H12F3N2O5]+ 117.055 [C5H9O3]+ [18]" exact="valaciclovir" post="325.162 [C13H21N6O4]+ 152.0577 [C5H6N5]+ [14,26] valganciclovir 355.172 [C12H23N6O5]+ 152.0577"/>
  <result pre="[C10H12F3N2O5]+ 117.055 [C5H9O3]+ [18] valaciclovir 325.162 [C13H21N6O4]+ 152.0577 [C5H6N5]+ [14,26]" exact="valganciclovir" post="355.172 [C12H23N6O5]+ 152.0577 [C5H6N5]+ [14,17] vidarabine 268.104 [C10H14N5O4]+ 136.062"/>
  <result pre="[C13H21N6O4]+ 152.0577 [C5H6N5]+ [14,26] valganciclovir 355.172 [C12H23N6O5]+ 152.0577 [C5H6N5]+ [14,17]" exact="vidarabine" post="268.104 [C10H14N5O4]+ 136.062 [C5H6N5]+ [27] viramidine/taribavirin 244.104 [C8H14N5O4]+ 112.062"/>
  <result pre="SRM product-ion Formula Literature brivudine 330.994 [C11H12B5N2O5]– 78.919 [Br]– [29]" exact="cidofovir" post="278.055 [C8H12N3O6P]– 237.065 [C7H14N2O5P]– [30] idoxuridine 352.964 [C9H10IN2O5]– 126.905"/>
  <result pre="[C11H12B5N2O5]– 78.919 [Br]– [29] cidofovir 278.055 [C8H12N3O6P]– 237.065 [C7H14N2O5P]– [30]" exact="idoxuridine" post="352.964 [C9H10IN2O5]– 126.905 [I]– [18] trifluridine 295.055 [C10H10F3N2O5]– 179.007"/>
  <result pre="[C8H12N3O6P]– 237.065 [C7H14N2O5P]– [30] idoxuridine 352.964 [C9H10IN2O5]– 126.905 [I]– [18]" exact="trifluridine" post="295.055 [C10H10F3N2O5]– 179.007 [CH2F3N2O2]– 3.1 Nucleoside analogues Most acyclic"/>
  <result pre="Herpes viruses are guanine-related compounds. Aciclovir ([M+H]+ with m/z 226)," exact="ganciclovir" post="([M+H]+ with m/z 256), penciclovir ([M+H]+ with m/z 254),"/>
  <result pre="Aciclovir ([M+H]+ with m/z 226), ganciclovir ([M+H]+ with m/z 256)," exact="penciclovir" post="([M+H]+ with m/z 254), valaciclovir ([M+H]+ with m/z 325),"/>
  <result pre="ganciclovir ([M+H]+ with m/z 256), penciclovir ([M+H]+ with m/z 254)," exact="valaciclovir" post="([M+H]+ with m/z 325), and valganciclovir ([M+H]+ with m/z"/>
  <result pre="([M+H]+ with m/z 254), valaciclovir ([M+H]+ with m/z 325), and" exact="valganciclovir" post="([M+H]+ with m/z 355) all show protonated guanine as"/>
  <result pre="to the loss of guanine N9-substituent (Fig. 1 ). For" exact="valaciclovir" post="and valganciclovir, the complementary ions due to the loss"/>
  <result pre="results in protonated 2-methylpropan-1-imine with m/z 72 ([C4H10N]+) for both" exact="valaciclovir" post="and valganciclovir (Fig. 1). Valaciclovir and valganciclovir are examples"/>
  <result pre="protonated 2-methylpropan-1-imine with m/z 72 ([C4H10N]+) for both valaciclovir and" exact="valganciclovir" post="(Fig. 1). Valaciclovir and valganciclovir are examples of amino-acid"/>
  <result pre="([C4H10N]+) for both valaciclovir and valganciclovir (Fig. 1). Valaciclovir and" exact="valganciclovir" post="are examples of amino-acid prodrugs of nucleoside antivirals. In"/>
  <result pre="in both positive-ion and negative-ion mode. In positive-ion mode for" exact="cidofovir" post="([M+H]+ with m/z 280), the product ion with m/z"/>
  <result pre="water is used in SRM. Based on similar structures, e.g.," exact="lamivudine" post="and zalcitabine, a product ion with m/z 112 ([C4H6N3O]+)"/>
  <result pre="ion with m/z 112 ([C4H6N3O]+) is most likely observed for" exact="cidofovir" post="as well. In negative-ion mode, cidofovir ([M−H]– with m/z"/>
  <result pre="most likely observed for cidofovir as well. In negative-ion mode," exact="cidofovir" post="([M−H]– with m/z 278) shows a product ion with"/>
  <result pre="the protonated 6-aminopurine or adenine ([C5H6N5]+) with m/z 136 for" exact="vidarabine" post="([M+H]+ with m/z 268), to the protonated 5-trifluoromethyl uracil"/>
  <result pre="268), to the protonated 5-trifluoromethyl uracil with m/z 181 for" exact="trifluridine" post="([M+H]+ with m/z 297) and to the protonated 5-iodouracil"/>
  <result pre="and to the protonated 5-iodouracil ([C4H4IN2O2]+) with m/z 239 for" exact="idoxuridine" post="([M+H]+ with m/z 355) (Fig. 2). However, for both"/>
  <result pre="idoxuridine ([M+H]+ with m/z 355) (Fig. 2). However, for both" exact="trifluridine" post="and idoxuridine, the 4-hydroxy-5-(hydroxymethyl)oxolan-2-ylium ion ([C5H9O3]+) with m/z 117"/>
  <result pre="next to two consecutive water losses [18]. In negative-ion MS–MS," exact="trifluridine" post="([M−H]– with m/z 295) shows the loss of the"/>
  <result pre="42 ([NCO]–), whereas for brivudine ([M−H]– with m/z 331) and" exact="idoxuridine" post="([M−H]– with m/z 353), a minor product ion due"/>
  <result pre="(I−) with m/z 127 (Fig. 2). Under ion-trap MS2 conditions," exact="idoxuridine" post="also shows the loss of hydrogen isocyanate (HNCO) to"/>
  <result pre="m/z of [M+H]+ Formula m/z of SRM product-ion Formula Literature" exact="amantadine" post="152.143 [C10H18N]+ 135.117 [C10H15]+ [[6], [7], [8],[32], [33], [34]]"/>
  <result pre="113.071 [C5H9N2O]+ [[4], [5], [6], [7], [8]] 69.045 [C3H5N2]+ [8]" exact="oseltamivir" post="313.212 [C16H29N2O4]+ 225.123 [C11H17N2O3]+ [6,7,36] 166.086 [C9H12NO2]+ [6,7] oseltamivir"/>
  <result pre="[8] oseltamivir 313.212 [C16H29N2O4]+ 225.123 [C11H17N2O3]+ [6,7,36] 166.086 [C9H12NO2]+ [6,7]" exact="oseltamivir" post="carboxylate 285.181 [C14H25N2O4]+ 138.055 [C7H8NO2]+ [6] 197.092 [C8H13N2O3]+ [6,36]"/>
  <result pre="oseltamivir carboxylate 285.181 [C14H25N2O4]+ 138.055 [C7H8NO2]+ [6] 197.092 [C8H13N2O3]+ [6,36]" exact="peramivir" post="329.218 [C15H29N4O4]+ 270.170 [C14H24NO4]+ [[37], [38], [39]] 100.112 [C6H14N]+"/>
  <result pre="329.218 [C15H29N4O4]+ 270.170 [C14H24NO4]+ [[37], [38], [39]] 100.112 [C6H14N]+ [40]" exact="rimantadine" post="180.175 [C12H22N]+ 163.148 [C12H19N]+ [[6], [7], [8],33] 135.117 [C10H15]+"/>
  <result pre="[C12H10BrNO2]+• [4] 479.082 [C22H2681BrN2O3S]+ 434.024 [C20H1981BrNO3S]+ [41] 280.986 [C12H1081BrNO2]+• [42]" exact="zanamivir" post="333.140 [C12H21N4O7]+ 60.056 [CH6N3]+ [[43], [44], [45]] 121.028 [C7H5O2]+"/>
  <result pre="[45] 4.1 M2 protein inhibitors against influenza A Amantadine and" exact="rimantadine" post="are inhibitors of the Matrix-2 protein, a proton-selective viroprotein,"/>
  <result pre="to prevent potential resistance issues in human, the use of" exact="amantadine" post="and rimantadine as antiviral agents during poultry farming has"/>
  <result pre="potential resistance issues in human, the use of amantadine and" exact="rimantadine" post="as antiviral agents during poultry farming has been banned"/>
  <result pre="Structures and the major product ions in positive-ion mode of" exact="amantadine" post="and rimantadine used against Influenza A viruses. Rimantadine ([M+H]+"/>
  <result pre="the major product ions in positive-ion mode of amantadine and" exact="rimantadine" post="used against Influenza A viruses. Rimantadine ([M+H]+ with m/z"/>
  <result pre="The initial fragmentation of the neuraminidase inhibitors laninamivir, peramivir, and" exact="zanamivir" post="is the loss of 59 Da, which can either"/>
  <result pre="guanidine [43], as also confirmed by accurate-m/z data, available for" exact="zanamivir" post="[47]. Either the ion with m/z 60 or the"/>
  <result pre="m/z 347) shows a product ion with m/z 60, whereas" exact="peramivir" post="([M+H]+ with m/z 329) shows a product ion with"/>
  <result pre="Structures and the major product ions in positive-ion mode of" exact="oseltamivir" post="and its carboxylate (desethyl) metabolite used against Influenza A"/>
  <result pre="Structures and the major product ions in positive-ion mode of" exact="peramivir" post="and zanamivir used against Influenza A viruses. The labeling"/>
  <result pre="the major product ions in positive-ion mode of peramivir and" exact="zanamivir" post="used against Influenza A viruses. The labeling position in"/>
  <result pre="as internal standard, is indicated with ∗. The fragmentation of" exact="zanamivir" post="is studied in detail in the course of an"/>
  <result pre="such as the small-molecule inhibitors camostat, nafamostat, as well as" exact="lopinavir" post="and ritonavir, known from HIV treatment. When SARS-CoV and"/>
  <result pre="in the discussion on the effectiveness of the antimalaria drugs" exact="chloroquine" post="and hydroxychloroquine in the treatment of Covid-19 [61]. Adequate"/>
  <result pre="discussion on the effectiveness of the antimalaria drugs chloroquine and" exact="hydroxychloroquine" post="in the treatment of Covid-19 [61]. Adequate clinical studies"/>
  <result pre="Compound class Compounds Status HIV-related agents lamuvidine, lopinavir, nelfinavir, ritonavir," exact="tenofovir" post="Discussed in part 1 [1]. HBV- or HCV-related agents"/>
  <result pre="part 2 [2]. Herpes-related agents aciclovir, brindicofovir, cidofovir, ganciclovir, letermovir," exact="valaciclovir" post="Discussed in this paper. Influenza-related agents umifenovir, zanamivir Discussed"/>
  <result pre="ganciclovir, letermovir, valaciclovir Discussed in this paper. Influenza-related agents umifenovir," exact="zanamivir" post="Discussed in this paper. Protein or peptide antiviral agents."/>
  <result pre="kDa), the cyclic peptide alisporivir (1215.9 Da), and the peptide" exact="thymalfasin" post="(3106.5 Da) Outside scope: no small-molecule antivirals. No MS–MS"/>
  <result pre="is attached to an aliphatic system, such as with peramivir," exact="zanamivir" post="and moroxydine (Fig. 6, Fig. 7). On the other"/>
  <result pre="small neutral losses. An illustrative example is the fragmentation of" exact="zanamivir" post="(Fig. 6). In yet other cases, the identity of"/>
  <result pre="in their generation. This is for instance the case for" exact="amantadine" post="and rimantadine (Fig. 4). The choices made in proposing"/>
  <result pre="generation. This is for instance the case for amantadine and" exact="rimantadine" post="(Fig. 4). The choices made in proposing structures for"/>
  <result pre="and heated electrospray ionization tandem mass spectrometryBiomed. Chromatogr.23200913214010.1002/bmc.109318823074 14SinghO.SaxenaS.MishraS.KhurooA.MonifT.Determination of" exact="valganciclovir" post="and ganciclovir in human plasma by liquid chromatography tandem"/>
  <result pre="electrospray ionization tandem mass spectrometryBiomed. Chromatogr.23200913214010.1002/bmc.109318823074 14SinghO.SaxenaS.MishraS.KhurooA.MonifT.Determination of valganciclovir and" exact="ganciclovir" post="in human plasma by liquid chromatography tandem mass spectrometric"/>
  <result pre="by liquid chromatography tandem mass spectrometric detectionClin. Biochem.44201190791510.1016/j.clinbiochem.2011.04.00321515246 15MomperJ.D.ZhangS.RandhawaP.S.ShapiroR.SchonderK.S.VenkataramananR.Determination of" exact="cidofovir" post="in human plasma after low dose drug administration using"/>
  <result pre="spectrometryJ. Pharmaceut. Biomed. Anal.5320101015102110.1016/j.jpba.2010.06.034 16RowerJ.E.NielsonC.ShiK.ParkA.H.Validation of an assay for quantifying" exact="ganciclovir" post="in dried blood spotsJ. Pharmaceut. Biomed. Anal.184202011318110.1016/j.jpba.2020.113181 17XuH.R.LiX.N.ChenW.L.LiuG.Y.ChuN.N.YuC.A sensitive"/>
  <result pre="17XuH.R.LiX.N.ChenW.L.LiuG.Y.ChuN.N.YuC.A sensitive assay for simultaneous determination of plasma concentrations of" exact="valganciclovir" post="and its active metabolite ganciclovir by LC/MS/MSJ. Chromatogr. B848200732933410.1016/j.jchromb.2006.10.053"/>
  <result pre="determination of plasma concentrations of valganciclovir and its active metabolite" exact="ganciclovir" post="by LC/MS/MSJ. Chromatogr. B848200732933410.1016/j.jchromb.2006.10.053 18KamelA.M.MunsonB.Collisionally-induced dissociation of substituted pyrimidine"/>
  <result pre="a high-performance liquid chromatography-tandem mass spectrometry for the determination of" exact="penciclovir" post="in human plasma: application to a bioequivalence studyJ. Chromatogr."/>
  <result pre="plasma: application to a bioequivalence studyJ. Chromatogr. B852200738238810.1016/j.jchromb.2007.01.044 21KannetiR.BhaveshD.ParamarD.ShivaprakashR.BhattP.A.Determination of" exact="penciclovir" post="in human plasma by liquid chromatography-electrospray ionization tandem mass"/>
  <result pre="accurate liquid chromatographic-tandem mass spectrometric method for the measurement of" exact="ribavirin" post="in rat and monkey plasmaJ. Chromatogr. B779200224124810.1016/s1570-0232(02)00379-3 25ShiX.ZhuD.LouJ.ZhuB.HuA.R.GanD.Evaluation of"/>
  <result pre="of a rapid method for the simultaneous quantification of ribavirin," exact="sofosbuvir" post="and its metabolite in rat plasma by UPLC-MS/MSJ. Chromatogr."/>
  <result pre="human plasma and its application to pharmacokinetic studiesChromatographia7320111089109510.1007/s10337-011-2001-y 30BreddemannA.HsienL.TotE.LäerS.Quantification of" exact="cidofovir" post="in human serum by LC-MS/MS for childrenJ. Chromatogr. B86120081910.1016/j.jchromb.2007.11.029"/>
  <result pre="nucleoside and nucleotide antiviralsMini Rev. Med. Chem.17201781883310.2174/138955751766617021615160128215138 32ArndtT.GuessregenB.HohlA.ReisJ.Determination of serum" exact="amantadine" post="by liquid chromatography-tandem mass spectrometryClin. Chim. Acta359200512513110.1016/j.cccn.2005.03.04015913590 33WuY.L.ChenR.X.XueY.YangT.ZhaoJ.ZhuY.Simultaneous determination"/>
  <result pre="liquid chromatography-tandem mass spectrometryClin. Chim. Acta359200512513110.1016/j.cccn.2005.03.04015913590 33WuY.L.ChenR.X.XueY.YangT.ZhaoJ.ZhuY.Simultaneous determination of amantadine," exact="rimantadine" post="and memantine in chicken muscle using multi-walled carbon nanotubes"/>
  <result pre="mass spectrometryClin. Chim. Acta359200512513110.1016/j.cccn.2005.03.04015913590 33WuY.L.ChenR.X.XueY.YangT.ZhaoJ.ZhuY.Simultaneous determination of amantadine, rimantadine and" exact="memantine" post="in chicken muscle using multi-walled carbon nanotubes as a"/>
  <result pre="of a liquid chromatographic-tandem mass spectrometric method for determination of" exact="oseltamivir" post="and its metabolite oseltamivir carboxylate in plasma, saliva and"/>
  <result pre="mass spectrometric method for determination of oseltamivir and its metabolite" exact="oseltamivir" post="carboxylate in plasma, saliva and urineJ. Chromatogr. B8592007748310.1016/j.jchromb.2007.09.018 37LindegardhN.HanpithakpongW.PhakdeerajA.SinghasivanonP.FarrarJ.HienT.T.WhiteN.J.DayN.P.Development"/>
  <result pre="chromatography-tandem mass spectrometry method for determination of the anti-influenza drug" exact="peramivir" post="in plasmaJ. Chromatogr. A1215200814515110.1016/j.chroma.2008.11.00919026421 38LiY.WangZ.LiX.GongW.XieX.YangY.ZhongW.ZhengA.In vitro evaluation of absorption"/>
  <result pre="plasmaJ. Chromatogr. A1215200814515110.1016/j.chroma.2008.11.00919026421 38LiY.WangZ.LiX.GongW.XieX.YangY.ZhongW.ZhengA.In vitro evaluation of absorption characteristics of" exact="peramivir" post="for oral deliveryEur. J. Drug Metab. Pharmacokinet.42201775776510.1007/s13318-016-0390-x28000173 39LeiM.GanW.SunY.HPLC-MS/MS analysis"/>
  <result pre="for oral deliveryEur. J. Drug Metab. Pharmacokinet.42201775776510.1007/s13318-016-0390-x28000173 39LeiM.GanW.SunY.HPLC-MS/MS analysis of" exact="peramivir" post="in rat plasma: elimination of matrix effect using the"/>
  <result pre="using the phospholipid-removal solid-phase extraction methodBiomed. Chromatogr. Mar.323201810.1002/bmc.4103 40LiY.ZhangX.WangX.LiS.RuanJ.ZhangZ.Quantification of" exact="peramivir" post="(a novel anti-influenza drug) in human plasma by hydrophilic"/>
  <result pre="mass spectrometric method for the determination of the neuraminidase inhibitor" exact="zanamivir" post="(GG167) in human serumJ. Chromatogr. B732199938339310.1016/s0378-4347(99)00306-0 44BaughmanT.M.WrightW.L.HuttonK.A.Determination of zanamivir"/>
  <result pre="inhibitor zanamivir (GG167) in human serumJ. Chromatogr. B732199938339310.1016/s0378-4347(99)00306-0 44BaughmanT.M.WrightW.L.HuttonK.A.Determination of" exact="zanamivir" post="in rat and monkey plasma by positive ion hydrophilic"/>
  <result pre="compounds - application for the antiviral drug ZanamivirTalanta141201516416910.1016/j.talanta.2015.03.06625966397 46XuY.RenC.HanD.GongX.ZhangX.HuangH.JiangF.CuiY.ZhengW.TianX.Analysis of" exact="amantadine" post="in Laminaria Japonica and seawater of Daqin Island by"/>
  <result pre="spectrometryJ. Chromatogr. B1126–1127201912169710.1016/j.jchromb.2019.06.024 47ZonjaB.GonçalvesC.PérezS.DelgadoA.PetrovicM.AlpenduradaM.F.BarcelóD.Evaluation of the phototransformation of the antiviral" exact="zanamivir" post="in surface waters through identification of transformation productsJ. Hazard"/>
  <result pre="productsJ. Hazard Mater.265201429630410.1016/j.jhazmat.2013.10.00824211180 48JunwalM.SahuA.HandaT.ShahR.P.SinghS.ICH guidance in practice: degradation behaviour of" exact="oseltamivir" post="phosphate under stress conditionsJ. Pharmaceut. Biomed. Anal.6220124860 49WangY.ChenX.LiQ.ZhongD.Metabolite identification"/>
  <result pre="of safe-in-man broad-spectrum antiviral agentsInt. J. Infect. Dis.93202026827610.1016/j.ijid.2020.02.01832081774 61FernerR.E.AronsonJ.K.Chloroquine and" exact="hydroxychloroquine" post="in covid-19BMJ3692020m143210.1136/bmj.m143232269046 62ZhangD.FuY.GaleJ.P.AubryA.F.ArnoldM.E.A sensitive method for the determination of"/>
  <result pre="hydroxychloroquine in covid-19BMJ3692020m143210.1136/bmj.m143232269046 62ZhangD.FuY.GaleJ.P.AubryA.F.ArnoldM.E.A sensitive method for the determination of" exact="entecavir" post="at picogram per milliliter level in human plasma by"/>
  <result pre="hepatic cytochrome P450 3A activity in healthy adults using intravenous" exact="midazolam" post="as a probeJ. Clin. Pharmacol.46200610310810.1177/009127000528328616397289 65AvataneoV.de NicolòA.CusatoJ.AntonucciM.MancaA.PalermitiA.WaittC.WalimbwaS.LamordeM.di PerriG.D’AvolioA.Development and"/>
 </snippets>
</snippetsTree>
